Wainer Andrea F 4
4 · ABBOTT LABORATORIES · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Wainer Andrea F
EXECUTIVE VICE PRESIDENT
Transactions
- Exercise/Conversion
Common shares without par value
2024-01-29$59.94/sh+17,500$1,048,950→ 82,527 total - Sale
Common shares without par value
2024-01-29$112.50/sh−17,500$1,968,750→ 65,027 total - Exercise/Conversion
Common shares without par value
2024-01-29$44.40/sh+25,000$1,110,000→ 90,027 total - Exercise/Conversion
Option (right to buy)
2024-01-29−17,500→ 46,949 totalExercise: $59.94From: 2021-02-16Exp: 2028-02-15→ Common Shares (17,500 underlying) - Sale
Common shares without par value
2024-01-29$112.50/sh−25,000$2,812,500→ 65,027 total - Exercise/Conversion
Option (right to buy)
2024-01-29−25,000→ 13,271 totalExercise: $44.40From: 2020-02-17Exp: 2027-02-16→ Common Shares (25,000 underlying)
Footnotes (2)
- [F1]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- [F2]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.